AzTrials
AzTrials

Complex Anal FistulaPhase 2/3FISCLOSENCT02336867

Therapeutic Management of Complex Anal Fistulas by Installing a Closure Clip: Multicentre Randomized Controlled Trial

A Phase 2/3 study testing Closure clip (OTSC® Proctology) in people with Complex Anal Fistula, run by University Hospital, Clermont-Ferrand at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Anal fistulas are the main etiology of perianal abscesses and suppurations. They are common and generally associated with pain, anal incontinence, impaired quality of life and work incapacity. The therapeutic management of this disease has a double objective: heal the suppuration and preserve the sphincter function. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Complex Anal Fistula
What is being tested?
Closure clip (OTSC® Proctology)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
92 participants
Where
1 siteFrance
Study dates
Jan 2015to Feb 2017
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Complex anal fistula (intersphincteric, trans-sphincteric, or even suprasphincteric, extrasphincteric) drained and requiring closing intervention of fistula.
  • Obtaining the patient's written consent
  • Naive patient to any surgical treatment for fistula closure
  • Patient receiving a social security scheme

Who cannot join

  • <18 years and> 80 years
  • BMI> 35 kg / m²
  • Rectovaginal or rectourethral fistulas
  • Infections : sepsis, tuberculosis or HIV
  • History of allergy to nickel
  • Cognitive disorders or major disability making it impossible to understand the study and signed an informed consent
Show all 10Show fewer
  • Already included in another clinical trial patients
  • breastfeeding or pregnancy
  • Legal incapacity (person deprived of liberty or guardianship)
  • Patients not compliant with the criteria of the study

Trial locations and contacts

1 site in 1 country.

France1 site, 1 recruiting
  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003

    Patrick LACARIN, 04 73 75 11 95, placarin@chu-clermontferrand.fr

    Recruiting

Other trials in France

About this study

Anal fistulas are the main etiology of perianal abscesses and suppurations. They are common and generally associated with pain, anal incontinence, impaired quality of life and work incapacity. The therapeutic management of this disease has a double objective: heal the suppuration and preserve the sphincter function. Each year, anal fistulas affect 1 in 10 000 in the normal population, with a difference in prevalence between men and women (1.23 per 10 000 men and 0.56 per 10 000 women). The average age of the patients was 40 years (Simpson et al., 2012).

In about 80% of cases, anal fistulas are secondary to an infection of Hermann and Desfosses' anal glands (cryptogenic or cryptoglandular). Infection of the anal gland can result in an abscess between the internal and external sphincters, which in turn can spread to other parts of the perianal region. The infection can follow many directions from this point in the intersphincteric plan. When the pus reaches the skin, the fistula is formed. Anal fistula therefore has always an intraductal origin, cryptic, with a primary port at this level, and the disregard of which causes the recurrence of the fistula; and usually a secondary port in the skin.

Read more

Fistulas are usually divided into two groups. The first group contains fistulas called "simple", which are intersphincteric fistulas or trans-sphincteric involving only the lower third of the sphincter complex. Fistulas usually didn't affect any muscle. The second group contains fistulas called "complex". These are intersphincteric, trans-sphincteric, or even suprasphincteric, extrasphincteric fistulas.

For many years, the treatment of choice was to open the fistula (fistulotomy), but this procedure was associated with a risk of incontinence, the consequences could be potentially devastating. Other surgical treatments include setons, fibrin glue, collagen plugs and advancement flap technique to cover internal opening of the fistula. The success of these therapies remains variable.

The advancement flap technique remains a strategy of choice in the treatment of anal fistulas and particularly in the case of complex fistulas. The success rate of the advancement flap technique remains variable across studies but a recent meta-analysis finds a success rate of around 60%.

A new technique for closing anal fistula is currently in development with the use of a closure clip nitinol (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners). This new technique has been validated in a porcine model of anal fistula, ensuring the safety of the device. A first case was published in a patient with complex anal fistula (high trans-sphincteric). After erosion fistula tract with a special brush, a nitinol clip (OTSC® Proctology) was deposited on the internal opening of the fistula. Eight months after surgery, the fistula was healed and the clip was removed by cutting with special pliers. This technique is currently being broadcast and dozens of patients were treated with this clip without any further scientific validation of the process.

To date, this innovative technique of the closure clip has not yet been assessed in a randomized controlled trial. It is therefore essential to carry out a prospective evaluation in order to determine the effectiveness and safety of this new device in the case of complex anal fistulas.

Read the detailed description

After validation of the inclusion and exclusion criteria, the patients included in this clinical trial will be randomized between the two arms of the study for the closure of the anal fistula:

  • Control group: advancement flap technique Experimental group: closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)

Follow up of the patients will be performed until 1 year after the intervention.

Being tested
Closure clip (OTSC® Proctology)
Keywords
Complex anal fistula, clip,

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Closure clip (OTSC® Proctology)Device

Study groups in NCT02336867
Study groupRoleWhat they receive
Experimental groupExperimentalclosure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
Receives: Device: Closure clip (OTSC® Proctology)
Control groupOtheradvancement flap technique
Receives: Device: Closure clip (OTSC® Proctology)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of patients with healed anal fistula

    The diagnosis will be made by the lack of leakage alleged by the patient for at least one month and found on clinical examination

    Measured: at 3 months after surgery

Secondary outcomes (5)
  1. Anal fistula healing

    Measured: at 6 months and 1 year

  2. VAS proctologic pain

    Measured: days 0, 1, 2, 3, 15, 30, 60, 90, 180 and 365

  3. Anal incontinence score (questionnaire Jorge and Wexner)

    Measured: days 0, 15, 30, 60, 90, 180 and 365

  4. Digestive disorders and quality of life (GIQLI questionnaire)

    Measured: days 0, 15, 30, 60, 90, 180 and 365

  5. Quality of life (EQ5D Questionnaire)

    Measured: days 0, 30, 90, 365

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2015 (estimated)
  2. Study startJan 2015
  3. Primary completionJan 2017 (estimated)
  4. Study completionFeb 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
92 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02336867
Sponsor's protocol ID
CHU-2018
Other IDs
2014-A00441-46
Acronym
FISCLOSE
Status last verified
Sep 2015
First submitted
8 Jan 2015
Last updated
22 Sep 2015
Results posted
No

Publications

  • Dubois A, Carrier G, Pereira B, Gillet B, Faucheron JL, Pezet D, Balayssac D. Therapeutic management of complex anal fistulas by installing a nitinol closure clip: study protocol of a multicentric randomised controlled trial--FISCLOSE. BMJ Open. 2015 Dec 16;5(12):e009884. doi: 10.1136/bmjopen-2015-009884.

    PubMed 26674505

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Closure clip (OTSC® Proctology) in people with Complex Anal Fistula, run by University Hospital, Clermont-Ferrand at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Patrick LACARIN (04 73 75 11 95, placarin@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients with healed anal fistula (time frame: at 3 months after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02336867, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in